FDA FIRST-ROUND IDE APPROVAL RATE CLIMBS TO 70%, ALPERT REPORTS AT RAPS MEETING; TIER 1 IN VITRO DIAGNOSTIC 510(k) REVIEWS AVERAGE 22 DAYS UNDER DCLD PILOT
This article was originally published in The Gray Sheet
FDA is approving 70% of investigational device exemption applications within the first 30-day review cycle, Susan Alpert, Director of FDA's Office of Device Evaluation, told attendees at the Regulatory Affairs Professionals Society annual meeting Sept. 10 in Washington, D.C. The agency's ability to improve the percentage of IDE applications approved in the first review cycle marks the "greatest success in terms of percentage turnaround" at ODE, Alpert said.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.